High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

NCT02629120 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

NIH

Sponsor class

Conditions

Chronic Granulomatous Disease Transplant

Interventions

DRUG: Alemtuzumab
DRUG: Busulfan
DRUG: Sirolimus
DRUG: Cyclophosphamide
RADIATION: Total Body Irradiation
BIOLOGICAL: Peripheral blood stem cells

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)